83 related articles for article (PubMed ID: 33067703)
1. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
[TBL] [Abstract][Full Text] [Related]
2. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract][Full Text] [Related]
3. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
4. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
5. Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study.
Demirkiran A; Eryilmaz MK; Karaagac M; Araz M; Korkmaz M; Koçak MZ; Artac M
J Cancer Res Ther; 2023; 19(3):595-600. PubMed ID: 37470581
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Molnár S; Beke L; Méhes G; Póka R
Pathol Oncol Res; 2020 Oct; 26(4):2549-2555. PubMed ID: 32594311
[TBL] [Abstract][Full Text] [Related]
7. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
[TBL] [Abstract][Full Text] [Related]
8. Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125.
Yang ST; Chang WH; Chou FW; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Nov; 62(6):802-808. PubMed ID: 38008497
[TBL] [Abstract][Full Text] [Related]
9. Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent Ovarian Cancer.
Oh SH; Park SJ; Lee S; Lee S; Kim HS
In Vivo; 2024; 38(1):467-473. PubMed ID: 38148089
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.
Taliento C; Morciano G; Nero C; Froyman W; Vizzielli G; Pavone M; Salvioli S; Tormen M; Fiorica F; Scutiero G; Scambia G; Giorgi C; Greco P; Pinton P
Int J Gynecol Cancer; 2024 Jun; 34(6):906-918. PubMed ID: 38658022
[TBL] [Abstract][Full Text] [Related]
11. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen.
Yang ST; Chang WH; Chou FW; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):10-16. PubMed ID: 38216242
[TBL] [Abstract][Full Text] [Related]
12. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
Wade KNS; Brady MF; Thai T; Wang Y; Zheng B; Salani R; Tewari KS; Gray HJ; Bakkum-Gamez JN; Burger RA; Moore KN; Bookman MA
Gynecol Oncol; 2019 Oct; 155(1):69-74. PubMed ID: 31409486
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic resensitization to platinum in ovarian cancer.
Matei D; Fang F; Shen C; Schilder J; Arnold A; Zeng Y; Berry WA; Huang T; Nephew KP
Cancer Res; 2012 May; 72(9):2197-205. PubMed ID: 22549947
[TBL] [Abstract][Full Text] [Related]
14. A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.
Defferrari C; Campora S; D'Amico M; Piccardo A; Biscaldi E; Rosselli D; Pasa A; Puntoni M; Gozza A; Gennari A; Zanardi S; Lionetto R; Bandelloni M; Decensi A
J Ovarian Res; 2012 Jun; 5(1):17. PubMed ID: 22732001
[TBL] [Abstract][Full Text] [Related]
15. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
Kus F; Guven DC; Yildirim HC; Chalabiyev E; Akyildiz A; Tatar OD; Sahin YB; Ileri S; Karaca E; Kertmen N; Arik Z
Biomark Med; 2023 Apr; 17(7):379-389. PubMed ID: 37309756
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.
Yang J; Cheng L; Zhang J; Chen L; Wang D; Guo X; Ma X
Medicine (Baltimore); 2018 Jul; 97(28):e11417. PubMed ID: 29995790
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients.
Cunnea P; Gorgy T; Petkos K; Gowers SAN; Lu H; Morera C; Wu W; Lawton P; Nixon K; Leong CL; Sorbi F; Domenici L; Paterson A; Curry E; Gabra H; Boutelle MG; Drakakis EM; Fotopoulou C
Sci Rep; 2018 Oct; 8(1):14695. PubMed ID: 30279418
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
Fardella E; Zanirato G; Magni M; Caldarelli N; Chiappella A; Dodero A; Ljevar S; Orsucci L; Re A; Usai SV; Stefoni V; Castellino C; Rossi FG; Pinto A; Carniti C; Corradini P
Br J Haematol; 2024 May; 204(5):1752-1756. PubMed ID: 38176400
[TBL] [Abstract][Full Text] [Related]
19. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE
Transl Oncol; 2024 May; 43():101914. PubMed ID: 38417292
[TBL] [Abstract][Full Text] [Related]
20. Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.
O'Connor JP; Jayson GC; Jackson A; Ghiorghiu D; Carrington BM; Rose CJ; Mills SJ; Swindell R; Roberts C; Mitchell CL; Parker GJ
Clin Cancer Res; 2007 Oct; 13(20):6130-5. PubMed ID: 17947478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
